|
|
|
| Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media. |
|
| |
| Because of your current interest in Pharm Exec Direct, we wanted you to be the first to know about our new bi-weekly e-newsletter, Pharm Exec Picks, committed to bringing you the most popular news and articles from the pharma space, as well as what's currently trending on social media. We hope you enjoy this issue, and are as excited about it as we are. To continue receiving Pharm Exec Picks, please take a moment to update your subscription details here |
|
|
| Top 5 Stories : |
|
FDA Readies Quality Metrics Measures
After almost two years of discussion and analysis, the FDA is finalizing a proposal for collecting data from manufacturers to help measure the performance of manufacturing operations and the quality of resulting drugs and biologics.
Read more
|
|
|
Pharma M&A: Diverse and Accelerating
Young & Partners takes a look at pharma M&A activity every quarter, as well as the pipeline of deals that are an indication of the M&A outlook. Peter Young shares some observations about the pharma M&A landscape.
Read more
|
|
|
|
|
Investing In African Healthcare: Study, Share, Act — And Grow
To identify some benchmarks for best practices in building a viable drugs business in Africa, Pharm Exec recently spoke with Steven Adjei, a native Ghanaian and founding partner of BlueCloud Healthcare, an investment advisory firm and start-up business “incubator” focused on opportunities in the sub-Saharan region.
Read more
|
|
|
Eruptions on Europe's Drug-Pricing Horizon
The centre-piece for the informal meeting of EU ministers of health was a discussion on the price of drugs, driven particularly by concerns over the cost of innovations such as Gilead's hepatitis C treatment, Sovaldi, on which the Italian and French health authorities have been leading the attacks.
Read more
|
|
|
| Trending on Social Media : |
Sunny Outlook for Outsourcing
The results of the 2014 edition of the PharmSource/Pharmaceutical Technology Outsourcing Survey show that strong growth for early-stage and mid-size bio/pharmaceutical companies is continuing.
Read more
|
BMS and Merck Race to Melanoma Treatment Market
Merck’s Keytruda, recently approved in the U.S. to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo.
Read more
|
EMA Calls Out to Companies Developing Ebola Treatments
EMA Executive Director, Guido Rasi, has asked the Committee for Medicinal Products for Human Use to perform a formal review of the available scientific information; companies are invited to send all available quality, preclinical and clinical data about their Ebola treatments under development for review.
Read more
|
|
|
| Follow Us |
|
|
|
|
|
